Harbin Medisan Pharmaceutical Co., Ltd.

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
10.28 ^CNY	-2.28%		+3.63%	-24.69%

04-26	Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	CI
04-26	Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	MT

Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021

May 18, 2022 at 03:48 pm

Harbin Medisan Pharmaceutical Co., Ltd. at its Annual General Meeting of 2021 on 17 May 2022 approved the profit distribution for 2021. The company announced final cash dividend/10 shares (tax included) of CCNY 3.20000000.

Latest news about Harbin Medisan Pharmaceutical Co., Ltd.

Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	04-26	CI
Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	04-26	MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022, Payable on May 31, 2023	23-05-17	CI
Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug	23-05-04	MT
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments	22-11-28	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Implements Final Cash Dividend for 2021, Payable on June 13, 2022	22-06-07	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021	22-05-18	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021	22-04-27	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-29	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2020, Payable on July 5, 2021	21-06-29	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020	21-05-19	CI
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020	21-04-28	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd..	21-02-28	CI
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million.	21-02-09	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-22	CI

Chart Harbin Medisan Pharmaceutical Co., Ltd.

Duration

Period

Chart Harbin Medisan Pharmaceutical Co., Ltd.

More charts

Company Profile

HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD.	-24.69%	440M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals